David B. Ridley - Publications, H-index & Citations

David B. Ridley

university of chicago

15H指数

82论文数

893被引数

收录论文 23

发表时间

The value of speed for drug developers 对于药物开发者的价值

Nature Reviews Drug Discovery

IF101.8

2026-09-18

PREAI

David B. Ridley; Chenxi Xu

European priority review vouchers for neglected disease product development

BMJ GLOBAL HEALTH

IF6.1

2024-01-30

OAAI

Ridley, David B.; Lasanta, Agustin Martin; Jones, Ffion Storer; Ridley, Sarah K.

FDA Global Drug Inspections: Surveillance Of Manufacturing Establishments Remains Well Below Pre-COVID-19 Levels

HEALTH AFFAIRS

IF8.1

2023-12-01

OAAI

Cuddy, Emily; Lu, Yun Peng; Ridley, David B.

Consequences of a shortage and rationing: Evidence from a pediatric vaccine

JOURNAL OF HEALTH ECONOMICS

IF3.6

2023-12-01

PREAI

Liebman, Eli; Lawler, Emily C.; Dunn, Abe; Ridley, David B.

US Tropical Disease Priority Review Vouchers: Lessons In Promoting Drug Development And Access

HEALTH AFFAIRS

IF8.1

2021-08-01

PREAI

Ridley, David B.; Ganapathy, Pranav; Kettler, Hannah E.

Does Medicare Reimbursement Drive Up Drug Launch Prices?

REVIEW OF ECONOMICS AND STATISTICS

IF6.8

2020-12-01

PREAI

Ridley, David B.; Lee, Chung-Ying

A Voucher System To Speed Review Could Promote A New Generation Of Insecticides To Fight Vector-Borne Diseases

HEALTH AFFAIRS

IF8.1

2017-08-01

OAAI

Ridley, David B.; Moe, Jeffrey L.; Hamon, Nick

The Role of Government Reimbursement in Drug Shortages

american economic journal macroeconomics

IF5.3

2017-05-01

OAAI

Yurukoglu, Ali; Liebman, Eli; Ridley, David B.

Real-World Data: Policy Issues Regarding their Access and Use

MEDICAL CARE

IF2.8

2016-12-01

PREAI

Basu, Anirban; Axelsen, Kirsten; Grabowski, David C.; Meltzer, David O.; Polsky, Daniel; Ridley, David B.; Wiederkehr, Daniel; Philipson, Tomas J.

Real-World Data: Responses to Zito and Doshi

MEDICAL CARE

IF2.8

2016-12-01

PREAI

Basu, Anirban; Axelsen, Kirsten; Grabowski, David C.; Meltzer, David O.; Polsky, Daniel; Ridley, David B.; Wiederkehr, Daniel; Philipson, Tomas J.

The Commercial Market For Priority Review Vouchers

HEALTH AFFAIRS

IF8.1

2016-05-01

OAAI

Ridley, David B.; Regnier, Stephane A.

Efficacy of the Priority Review Voucher Program

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IF55

2016-04-19

PREAI

Ridley, David B.; Dent, Jennifer; Egerton-Warburton, Christopher

No Shot: US Vaccine Prices And Shortages

HEALTH AFFAIRS

IF8.1

2016-02-01

OAAI

Ridley, David B.; Bei, Xiaoshu; Liebman, Eli B.

MARKET WATCH Forecasting market share in the US pharmaceutical market

NATURE REVIEWS DRUG DISCOVERY

IF101.8

2015-08-14

OAAI

Regnier, Stephane A.; Ridley, David B.

Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases

LANCET

IF88.5

2010-09-01

PREAI

Ridley, David B.; Calles Sanchez, Alfonso

International price comparisons for novel and follow-on drugs

VALUE IN HEALTH

IF6

2007-11-01

OAAI

Ridley, David B.

Would greater transparency and uniformity of health care prices benefit poor patients?

HEALTH AFFAIRS

IF8.1

2007-09-01

OAAI

Kyle, Margaret K.; Ridley, David B.

Impact of medicaid preferred drug lists on therapeutic adherence

VALUE IN HEALTH

IF6

2007-05-01

OAAI

Ridley, D.; Axelsen, K. J.

Vouchers: The authors respond

HEALTH AFFAIRS

IF8.1

2006-07-01

PREAI

Ridley, David B.

Postapproval drug safety: The authors respond

HEALTH AFFAIRS

IF8.1

2006-07-01

PREAI

Ridley, David B.; Kramer, Judith M.

研究方向